Golden Cross; Situation Update ~ World War III and the Imminent Collapse of the US Dollar.
Situation Update Published July 16, 2022



https://rumble.com/v1ci0qj-situation-update-world-war-iii-and-the-imminent-collapse-of-the-us-dollar..html

JUDY BYINGTON INTEL: RESTORED REPUBLIC VIA A GCR HUGE UPDATE AS OF JULY 16, 2022 - TRUMP NEWS
Trump News Channel Published July 16, 2022



https://rumble.com/v1chjk7-judy-byington-intel-restored-republic-via-a-gcr-huge-update-as-of-july-16-2.html

UPDATES COMING IN THE NEXT 24H - DONALD TRUMP INITIATED A CONTINUITY OF GOVERNMENT PLAN
Trump News Channel Published July 15, 2022



https://rumble.com/v1ce91j-updates-coming-in-the-next-24h-donald-trump-initiated-a-continuity-of-gover.html?mref=6zof&mrefc=8

Clif High: The Jabbed Are About To Get A Rude Awakening!
Patriot Movement Published July 15, 2022



https://rumble.com/v1ceigp-clif-high-the-jabbed-are-about-to-get-a-rude-awakening.html

BIG SITUATION SHOCKING NEWS & JUDY BYINGTON INTEL UPDATE TODAY 07/11/2022 - TRUMP NEWS
Trump News Channel Published July 15, 2022



https://rumble.com/v1ce7lv-big-situation-shocking-news-and-judy-byington-intel-update-today-07112022-t.html


PRESIDENT DONALD J. TRUMP LIVE FROM PRESCOTT, AZ JULY 22ND, 2022
by RSBN Studio
07/13/22

President Donald J. Trump, 45th President of the United States of America, will be
joined by endorsed candidates, members of the Arizona congressional delegation,
and other special guests on Saturday, July 22, 2022, in Prescott Valley, AZ.
This Save America rally is a continuation of President Trump’s unprecedented effort
to advance the MAGA agenda by energizing voters and highlighting America First candidates and causes.

((( Saturday, July 22, 2022, at 4:00 PM MST )))

President Donald J. Trump, 45th President of the United States of America, Delivers Remarks

https://www.rsbnetwork.com/video/president-donald-j-trump-live-from-prescott-az-july-16th-2022/?mc_cid=d10c22f780&mc_eid=a19c8148b2
Venue:

Findlay Toyota Center

3201 Main St.

Prescott Valley, AZ 86314

Special Guest Speaker:

Kari Lake, Trump Endorsed Candidate for Governor of Arizona

Blake Masters, Trump Endorsed Candidate for U.S. Senate in Arizona

Abe Hamadeh, Trump Endorsed Candidate for Attorney General of Arizona

State Rep. Mark Finchem, Trump Endorsed Candidate for Secretary of State of Arizona
and State Representative from Arizona’s 11th District

Sheriff Mark Lamb, Pinal County Sheriff

Kelli Ward, Chairwoman of the Republican Party of Arizona

Mike Lindell, Inventor and CEO of My Pillow

Timeline of Events:

6:00AM – Parking and Line Opens

11:00AM – Doors Open and Entertainment Begins

1:00PM – Special Guest Speakers Deliver Remarks

4:00PM – 45th President of the United States Donald J. Trump Delivers Remarks

General Admission Tickets:

REGISTER HERE

Request Media Credentials:

REGISTER HERE

All requests for media credentials must be submitted by Thursday, July 14, 2022, at 4:00PM MST.

https://www.rsbnetwork.com/video/president-donald-j-trump-live-from-prescott-az-july-16th-2022/?mc_cid=d10c22f780&mc_eid=a19c8148b2

CDD; SOUND THE ALARM! DECISION SOON? DURHAM MOVES! BIDEN EXPOSURE! NATO EXPOSED! NOW! PRAY!
Trump News Channel Published July 15, 2022



https://rumble.com/v1ce6ot-7.14.22-sound-the-alarm-decision-soon-durham-moves-biden-exposure-nato-expo.html

Are Corrupt Feds Distracting Us From The Truth About Everything? | Justinformed News
Patriot Movement Published July 15, 2022



https://rumble.com/v1cbzon-are-corrupt-feds-distracting-us-from-the-truth-about-everything-justinforme.html


ATTENTION! Dr. 'Judy Mikovits' "WARNING TO HUMANITY" 'David Nino Rodriguez' Interview
AndreCorbeil Published July 12, 2022



https://rumble.com/v1c1qal-attention-dr.-judy-mikovits-warning-to-humanity-david-nino-rodriguez-interv.html

US Navy Revolt Slams Biden Secret Plot To Oust Over 500,000 Troops

https://www.whatdoesitmean.com/index3977.htm

Iran Plotting to Assassinate Trump and Pompeo in Revenge for Soleimani Killing, US Intel Leak Shows
David HawkinsJuly 14, 20222 Comments

https://slaynews.com/news/us-intel-leak-says-iran-plotting-to-assassinate-donald-trump-and-mike-pompeo-in-revenge-for-soleimani-drone-strike/

2000 MULES BY DINESH D’SOUZA DOCUMENTARY - best news here

This is the official 2000 Mules movie.“2000 Mules,” a documentary film created
by Dinesh D’Souza, exposes widespread, coordinated voter fraud in the 2020
election, sufficient to change the overall outcome. Drawing on research provided
by the election integrity group True the Vote, “2000 Mules” offer..

https://bestnewshere.com/2000-mules-by-dinesh-dsouza-documentary/

THE EU FINALLY ADMITS THE VACCINE DESTROYS YOUR IMMUNE SYSTEM COMPLETELY - TRUMP NEWS
Trump News Channel Published July 10, 2022



https://rumble.com/v1bqnvt-the-eu-finally-admits-the-vaccine-destroys-your-immune-system-completely-tr.html

$CH Excellent Video Thanks;

https://live.aflds.org/

God Bless America
Amen

This is very, VERY big news …

JPMorgan says Bitcoin could hit $130,000.

Ex-Goldman Sachs executive Raoul Pal seems to think that’s way too low.

And Ark Invest — sponsor of two of the best performing tech ETFs of the past two years — expects Bitcoin’s total market cap to surpass gold’s.

Wow! To do that, Bitcoin would probably have to surpass $500,000 per coin.

Bitcoin (BTCUSD)
37175.49 ? 82.77 (0.220%)
Volume: 2,022.026 @01/28/22 1:09:08 AM UTC
Bid Ask Day's Range
37,171.03 37,171.72 37101.78 - 37500.00
BTCUSD Detailed Quote

dis is really good --- $OWUV ---what ah break for many bagholders.
OTC DISCLOSURE & NEWS SERVICE

https://www.otcmarkets.com/stock/OWUV/news/One-World-Universe-Creates-New-Subsidiary-Focusing-on-the-Revival-of-Expert-Market-Listed-Companies?id=337309

One World Universe Creates New Subsidiary Focusing on the Revival
of Expert Market Listed Companies
Press Release | 12/30/2021
HUNTINGTON BEACH, CA, Dec. 30, 2021 (GLOBE NEWSWIRE) --
via NewMediaWire --
One World Universe Inc. (OTC: OWUV), a publicly traded company that invests in sports related businesses,

distressed assets, business opportunities within emerging industries

such as the Metaverse and providing humanitarian efforts in over 185 countries,

announced today it has formed a new division of the company that
will focus on the revival of Expert Market listed companies.

The newly created entity will be led by CFO Caren Currier, known
and respected in the OTC world for her uncanny ability to clean up distressed and dormant public companies.

One World Universe will act as an incubator and accelerator of these public vehicles and will either assist in the reverse merger process
of the “shells”

where Ms. Currier will find a qualified owner for the entity
or will simply clean up the vehicle for the current company’s
executive officer.

One World shall generate revenue through charging a flat fee share equity in the company as compensation for services provided.

These shares will be part of a portfolio of stock equity assets generated from both “clean ups” and “spin offs” of current
subsidiaries in the future.

“Many shareholders in the investment community have seen my name attached to other public entities.

I have many years’ experiences in cleaning up public companies and getting them back up and trading after having them meet all necessary regulatory requirements and even facilitating reverse mergers.

After the recent rule change this past September,
my services have been sought after by many company owners who need assistance in reviving their public entity
and requalifying it to trade back on the Pink Sheets market tier or higher,” stated Caren Currier, CFO of OWUV.

On September 28, 2021, more than 2,000 publicly traded companies whose shares had been quoted on OTC Markets Group’s Pink Open Market were shifted to OTC Markets’ limited “Expert Market,” where stocks were essentially suspended from official trading, for failure to make current information about the company publicly available.

This action was the result of the SEC’s position that enhanced disclosure and investor protection were needed in the
over-the-counter (OTC) markets, as reflected in the September 2020 amendment to Securities Exchange Act Rule 15c2-11.

This rule prohibits dealers
from publishing quotations for OTC securities to quotation mediums without first reviewing certain issuer financial information and ensuring that information is current and publicly available.

For further updates and information, shareholders are asked to follow our social media accounts on twitter at www.twitter.com/JCHC_UPWT and http://www.twitter.com/OneWorldU or visit our websites at
http://www.oneworlduniverseinc.com and
http://www.JCHoldingCorp.com.

About One World Universe, Inc.

One World Universe (OTC:OWUV) is a California corporation whose
mission driven business is implementing global humanitarian efforts through the profits generated from the sales of products and services

to improve people's lives living in the harshest environments
and their communities. Our company has contributed valuable
resources such as access to (PPE) personal protective equipment, medications, vaccines, and educational support programs where
play and basic necessities are essential.

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved.

Forward-looking statements are based on information available at
the time the statements are made and involve known and unknown risks,

uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from

the information expressed or implied by the forward-looking statements in this press release.

This press release should be considered in light of all filings of
the Company that
are contained in the Edgar Archives of the Securities and Exchange Commission at

http://www.sec.gov and in OTC Markets at

http://www.otcmarkets.com

Investor Relations Contact

Dana Salzarulo

Director Investor Relations

Info@jcholdingcorp.com

1-833-333-5242 Office

USEI

GRNH

BTZI

MJNA

ERBB

CRO Coin BURNING COINS EVERY SECOND! Crypto.com ARENA Debut NOW will 20x CRO?
24,579 viewsDec 25, 2021

Smart $ Loading SHIB here...Banner_2022_on_the_way!

3 Growth Stocks With More Potential Than Any Cryptocurrency $TDOC $ISRG
$VXRT
[Uu

Cryptocurrencies have taken over where last year's coronavirus vaccine stocks left off. The company holds more than 79% of the market, according to BIS Research.

KEY POINTS
The first company is proving it can be a solid pandemic and post-pandemic player.
The second stock is the leader by far in its field.
The third company is working on game-changing vaccine candidates.
Motley Fool Issues Rare “All In” Buy Alert

Revenue could skyrocket at these healthcare companies.
Cryptocurrencies have taken over where last year's coronavirus vaccine stocks left off. And their gains have been even bigger. For example, vaccine stock Novavax soared 2,700% last year. This year, much talked about meme coin Shiba Inu has surged a whopping 45,000,000%. In the short term, crypto players have been the golden ticket.

But the long-term growth picture for cryptocurrencies still is unclear. That's because it's a new industry and we don't yet know if use of these platforms will truly take off -- and which ones will dominate. So, if you're looking for a bit more visibility, you may want to check out a few healthcare growth stocks. I've chosen three with more long-term potential than any crypto player.

1. Teladoc
Teladoc Health ( TDOC -1.22% ) had a great 2020. Investors flocked to shares of the telehealth company. That's because the pandemic led more and more people to try online medical visits -- and revenue and visits skyrocketed. But this year hasn't been so great for Teladoc investors. The shares are heading for a 52% decline. The problem? Some worry patients will abandon online medical visits once the pandemic is over.

Teladoc has given us solid clues that its success isn't chained to the pandemic. The health crisis continues -- but lockdowns are no longer in place and people have returned to their routines. And at the same time, Teladoc still is growing. The company reported a 81% increase in revenue and a 37% gain in patient visits in the most recent quarter. Teladoc's "whole person" approach also is keeping patients coming back for all or most of their medical needs. For instance, 24% of chronic care members have signed up for multiple programs. And Teladoc predicts total patient visits this year will increase by at least 37% from last year.

This year won't be the best for Teladoc from a stock performance perspective. But with a strong financial picture and increasing platform use, everything is in place for major business and share price growth over the long term.

==========================================================


2. Intuitive
Intuitive Surgical ( ISRG 0.15% ) is the leader in the robotic surgery market. The company holds more than 79% of the market, according to BIS Research. Intuitive's Da Vinci robot helps surgeons perform minimally invasive procedures in areas such as general surgery, urology, and gynecology. This flagship product has been involved in more than 8.5 million procedures worldwide.

Intuitive sells the Da Vinci system for about $2 million. And it has about 6,525 systems installed throughout the world. But what's most interesting is Intuitive doesn't generate revenue uniquely through sales of the Da Vinci. Intuitive also makes money through leasing of the systems. And Intuitive actually makes most of its revenue from selling instruments and accessories and services. Each system uses accessories -- some of which are disposable so must be replaced for each procedure. And services involve maintenance of the robotic system. Sales of instruments, accessories, and services together surpass that of the surgical systems.

Intuitive recently did a three-for-one stock split. It's share price had surpassed $1,000 a share. This was a great move because it opened the door for more investors to get in on this dynamic stock. Will the stock once again surpass $1,000? Intuitive's market share and growth make it very likely.

=============================================================

3. Vaxart
Vaxart ( VXRT -0.16% ) represents more risk than the other companies I've mentioned. That's because this company doesn't yet have products on the market. But if you're an aggressive investor, you might want to check it out. That's because if this biotech company does bring a candidate to the finish line, the company and investors may win big.

Why? Vaxart's technology could be game-changing. The company is working on oral vaccines. Yes, you just read that right: vaccines you can take as a pill with a glass of water. This is a plus for patients because it doesn't involve a needle stick. And it's a plus for healthcare systems because these potential vaccines are room temperature stable. That means they don't require refrigeration. And the small size of a pill means you can store a lot of product in a small space.

Right now, Vaxart is working on one of the most sought-after products: a coronavirus vaccine. The company's candidate is in a phase 2 trial. Vaxart expects to report trial data in the first quarter of 2022. The biotech company has five other non-coronavirus vaccine candidates in the pipeline. Farthest along is a seasonal flu candidate in phase 2 studies.

Vaxart shares are trading about $3 lower than even Wall Street's most pessimistic 12-month share price forecast. If the company delivers positive news from its coronavirus vaccine trial, the stock clearly could gain. And if Vaxart is able to bring a product to market, the stock may skyrocket.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool owns and recommends Intuitive Surgical and Teladoc Health. The Motley Fool recommends the following options: long January 2022 $193.33 calls on Intuitive Surgical and short January 2022 $200 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.

ORIGINAL PATENT IS CRAIG WRIGHT [he was Satoshi Nakamoto]

Miami jury rules in favor of Craig Wright, who claimed to invent bitcoin
PUBLISHED MON, DEC 6 20214:59 PM ESTUPDATED TUE, DEC 7 20212:51 AM EST
MacKenzie Sigalos
@KENZIESIGALOS

https://www.cnbc.com/2021/12/06/miami-jury-rules-in-favor-of-craig-wright-bitcoin-claimed-inventor.html

Australian computer scientist Craig Wright prevailed in a Miami civil case that pitted him against the family of his late business partner and computer forensics expert, David Kleiman.

At stake was half of both the 1.1 million bitcoin mined and
held by Satoshi,
a cache currently worth around $54 billion.

Had Wright lost the case, he would have had to produce the Satoshi cache of coins in order to pay the estate. But Wright did say that he would prove his ownership were he to win at trial. He also promised to donate much of his bitcoin fortune to charity, were he to prove victorious.

A man who has claimed to be the inventor of bitcoin just won a major U.S. court case, saving him from paying a former business partner tens of billions of dollars in the cryptocurrency.

Australian computer scientist Craig Wright implied in a 2016 blog post that he was Satoshi Nakamoto, the pseudonym used by the person or persons who developed bitcoin. Many in the crypto community are skeptical of Wright’s claim, in part because he has not moved any of the early bitcoin presumed to have been mined by Satoshi.

On Monday, Wright prevailed in a Miami civil case that pitted him against the family of his late business partner and computer forensics expert, David Kleiman. At stake was half of the 1.1 million bitcoin mined and held by Satoshi, a cache currently worth around $54 billion. The estate also claimed rights to some of the intellectual property behind early blockchain technology.

The prosecution argued that Kleiman was a co-creator of bitcoin, alongside Wright, entitling him to half of Satoshi’s assumed fortune. A federal jury in West Palm Beach sided with Wright and declined to award any of the bitcoin to Kleiman’s estate.

However, Wright was ordered to pay $100 million in compensatory damages over a breach in intellectual property rights related to W&K Info Defense Research LLC, a joint venture between the two men. That money will go to W&K directly, rather than to the Kleiman estate.

“We are immensely gratified that our client, W&K Information Defense Research LLC, has won $100,000,000 reflecting that Craig Wright wrongfully took bitcoin-related assets from W&K,” said counsel for W&K.

“This has been a remarkably good outcome, and I feel completely vindicated,” Wright said in a video posted to Twitter immediately following the verdict.

The Satoshi Nakamoto mystery
The mystery surrounding the founding of bitcoin is a big part of why this South Florida civil suit drew so much attention.

In 2008, just as the financial crisis was taking hold in the U.S., Satoshi Nakamoto published a nine-page white paper detailing a vision for bitcoin — a “peer-to-peer electronic cash system” that would function outside the reach of governments.

A few months later, Nakamoto released software that allowed users to mine for the cryptocurrency.

Mining for cryptocurrencies is the computationally intensive process by which new tokens are created and transactions of existing digital coins are verified. In the early days of bitcoin, it was possible to mine for it on a home PC. At the time, winning a block yielded a reward of 50 bitcoin. Today, the process requires specialized equipment, is mostly done at scale by professionals, and thanks to an anti-inflationary measure baked into the code, the block reward is down to 6.25 bitcoin.

Nakamoto, who could be one person or a consortium of coders, remained on the scene until 2011, at which point he abruptly left the project after emailing a fellow developer to say that they had “moved on to other things.” Before vanishing, the enigmatic creator is believed to have mined as many as 1.1 million bitcoin.

Had Wright lost the case, he would have had to produce the Satoshi cache of coins in order to pay the estate. But Wright did say that he would prove his ownership were he to win at trial. He also promised to donate much of his bitcoin fortune to charity, were he to prove victorious.

DeFi and Multi-Trillion Dollars Cryptocurrency Market, Introduces Decentralized Exchange (DEX)

Crypto.com COIN to $100 - CRO COIN PRICE PREDICTION NEWS! Crypto.com URGENT update ??
14,488 viewsNov 27, 2021

THANK YOU, HAPPY WKEND

FERN can hit $0.4 SOON! HERES WHY! $0.04?$0.1?0.4??! DETAILED ANALYSIS! - Dont miss a 10x ??
956 viewsSep 28, 2021

Yes, nice board you have here... GL

yes indeed big % gains last couple wks

The price of Bitcoin, Ethereum, and other cryptocurrencies is making a bull case for penny stocks with exposure to cryptocurrency. Whether it’s mining, some type of retail sales, fintech platform development, NFT, or “other,” the trend is apparent in the stock market today. Bitcoin prices jumped big overnight between the November 1 and November 2 sessions. The cryptocurrency continues rebounding from its end-of-September slump and now trades back above $63,000 a coin.

$SHIB starting the week off strong $$$$

CANNABIS TABS


https://thecbdblends.com/microsoft-wants-to-use-hemp-and-seaweed-to-build-sustainable-buildings/

https://thecbdblends.com/category/news/

https://thecbdblends.com/

https://thecbdblends.com/shop/

https://thecbdblends.com/category/edibles/

https://thecbdblends.com/category/cannabis/

https://thecbdblends.com/category/featured/

https://thecbdblends.com/

https://thecbdblends.com/category/culture/

https://thecbdblends.com/blog/

elliote wave theory

https://www.billionaireclubcollc.com/buy-after-an-elliott-wave-5-wave-decline-35/

[-chart]investorshub.advfn.com/uimage/uploads/2017/2/16/vvrclElliott_Wave_Decline_8_Wave.png[/chart]

[-chart]investorshub.advfn.com/uimage/uploads/2017/2/16/hgymrElliott_Wave_Chart.png[/chart]

[-chart]investorshub.advfn.com/uimage/uploads/2018/1/20/dwhgpElliott_Wave_Cycle_Chart_with_Wave_labels.png[/chart]









Elliott Wave Basics
http://www.acrotec.com/ewt.htm

Elliott Wave Theory
http://ta.mql4.com/elliott_wave_theory

Buy after an Elliott Wave,
5-Wave decline sequence !

A Basic “A,B,C Corrective Wave”

Buy, ONLY when the stocks price,
is trading under the Blue 8-day M.A.
when the Blue 8-day M.A. is under the Red 34-day M.A.


when;$nouv

[-chart]investorshub.advfn.com/uimage/uploads/2019/3/28/egrofNOUV_Mar_28_Chart_570_day_Weekly_shows_a_5_Wave_Decline_from_0.0006_Big_Green_Vol_Bar_of_4_Billion_shares_to_0.0001.png[/chart]

good repore' 'HPIL Holdings (HPIL)'

re;
Momentum is building
Many will be left chasing
Count on
Hpil and Mr Brown will get it done

15 powertrain patents

2 residentials?(wow)

7 partners

Ansys NDA

Zippa launch

Nft(140 plus)

Ev Motorcyclers

Apogee d7 cars

Medusa AI

INCREDIBLE cheap

Not for long

interesting https://dcdirtylaundry.com/

https://dcdirtylaundry.com/covid-19-moderna-gets-its-miracle/

Bitcoin (BTCUSD)
60399.98 ? -1483.81000000 (-2.40000000%)
Volume: 8,078.661 @10/31/21 4:10:54 PM UTC
Bid Ask Day's Range
60,399.98 60,399.99 60001.00 - 62427.02
BTCUSD Detailed Quote

BITCOIN
https://investorshub.advfn.com/Bitcoin-26047

there was no inflation in trump's yrs.
now almost 50% price increases
gasoline held around $2.35 for four yrs.
groceries now sky is da limit & got money
no food or paper goods on shelves.
borders ????? no control
& shots unconstitutional

YA COIN COLLECTOR MY FRIEND ????? $ANYONE ????? MORGAN & PEACE DOLLARS

https://www.trustpilot.com/review/coinadvisor.com?utm_medium=Trustbox&utm_source=EmailNewsletter3

$HPIL YIELD SIGN WILL BE REMOVED
Senator Cicero

Cyberlux Corp (OTCMKTS: $CYBL) has announced its most essential accomplishments on September 2021. A statement given by the company’s CEO Mark Schmidt reveals its achievements.

https://factsaboutcbd.org/cyberlux-corp-otcmkts-cybl-gives-update-on-its-accomplishments-for-september-2021-5136

Achievements Cyberlux made in September
One such achievement is the hiring of a new General Manager and Executive Vice President for Cyberlux’s FlightEye Drone Solutions. Larson Isley, who will take on this role, has vast experience as a Consulting Scientist and Guidance System Expert.

The company also introduced its FlightGDN platform to take advantage of UAS and its future capabilities. FlightGDN is a technology platform focussed on supporting high-tech military-grade UAS solution packages and products. It incorporates Cyberlux technologies and also uses third party technology such as VR/AR perception technologies, LiDAR mapping, infrared night vision and, LED lighting. The company also refreshed its website on September 30.

Cyberlux completed the acquisition of CTMC Drone Solutions, LLC, which will make up its drone technology platform. The company made the transaction with a series of cash payments, cashless warrants and shares of common stock. Cyberlux plans to use this same structure with its future acquisitions.

The company also partnered with Strike Group, LLC to promote the contracting and adoption of Cyberlux Infrastructure products such as solar power solutions and LED street lighting. It was also to promote products by Flight Eye Drone Solutions.

Yahoo has also identified Cyberlux as one of the ten best Micro-cap stocks for investors.

Cyberlux’s plans
Cyberlux is making plans to announce the hiring of a new staff member who will be instrumental in improving its Unmanned Aircraft Systems Business. The new hire is said to have significant reach with U.S agencies.

The company will also announce a new acquisition. This acquisition will help Cyberlux penetrate European and U.S markets. Another Cyberlux platform acquisition will be closed by the end of October.

Meanwhile, Cyberlux will continue to execute its Alpha growth plan. The plan consists of three objectives. The first is to accelerate growth acquisitions, aggressive strategies, and partnerships. The second objective is to focus on the target market with DoD products and new technology. The final aim is to get OTC Pink Current Information Status to gain velocity.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
RELATED TOPICS:CYBERLUX CORP (OTCMKTS: CYBL)CYBLCYBL NEWSCYBL STOCKOTC CYB

cannabis https://factsaboutcbd.org/ excerpt $cybl

https://factsaboutcbd.org/category/benefits-of-cbd

https://factsaboutcbd.org/

https://factsaboutcbd.org/category/news

https://factsaboutcbd.org/cyberlux-corp-otcmkts-cybl-gives-update-on-its-accomplishments-for-september-2021-5136

https://factsaboutcbd.org/category/business

$CYBL COURTESY OF $CYBL
Office of Energy Efficiency and Renewable Energy
@eeregov
Nearly $40M for 40 projects + 2 requests for information + 1 notice of intent = 1 giant leap for solar energy and our pathway to a zero-carbon grid!

Learn about the projects and other efforts that will advance solar, storage & industrial technology: https://energy.gov/articles/doe-awards-nearly-40-million-grid-decarbonizing-solar-technologies

CANNABIS 8 BIG ONES
[-chart]insiderfinancial.com/wp-content/uploads/2021/02/Mushroom-Performance-1024x259.jpg[/chart]

Four Phantoms Medley ft. Sarah Brightman | The Phantom of The Opera
1,624,228 viewsOct 19, 2020

THIS $0.04 Penny Stock IS FIGHTING FOR $300 BILLION ?? once in a lifetime? ??
1,205 viewsOct 11, 2021

https://www.tinygems.net/emails/newsletter-landing-1021.html#2

Leonard Cohen - Hallelujah (Live In London)
195,791,358 viewsOct 2, 2009

https://www.stck.pro/news/ABUS/16133575

$payo New York City-based Marketing Collaborative Rosie Labs Brings Unique "UnAgency" Approach to Israeli Startups with Launch in Tel Aviv
October 07 2021 - 09:00AM
PR Newswire (US)

http://ih.advfn.com/stock-market/NASDAQ/payoneer-global-PAYO/stock-news/86239924/new-york-city-based-marketing-collaborative-rosie

NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Rosie Labs, a New York City-based marketing services collaborative, today announced the launch of a Tel Aviv branch, enabling fast-growing Israeli companies to leverage the Labs' expertise when entering and scaling in the U.S. The expansion is the first for Rosie Labs, a group of experienced, independent practitioners whose flexible, efficient approach, in stark contrast to that of traditional agencies, has driven exponential growth since early 2020.

The new practice will be led by Ronit Druker, a marketing and management expert who spent decades helping leading Israeli tech companies such as CheckPoint (Nasdaq: CHKP) and Payoneer (Nasdaq: PAYO) successfully penetrate the U.S. market. In her new role, Druker will collaborate with up-and-coming startups and mid-sized companies, following the Rosie Labs' approach to building curated services and bespoke teams based on each company's specific needs and objectives.

Rosie Labs has created a flexible model that will meet the rapidly growing needs of startups into corporate clients.

"Israel is a hotbed of technological innovation, yet despite the high concentration of incredible talents and promising companies, geography is often a perceived barrier that prevents them from expanding their presence to the U.S.," said Ronit Druker. "Rosie Labs has the right network of talent who have vast experience working with Israeli companies, and by expanding our services to these innovators in their market, we can eliminate those barriers using comprehensive, dynamic marketing, technology and sales solutions."

Coinciding with the geographic expansion for Rosie Labs, founder and CEO David Song has appointed Shauna Lagatol to lead global operations. Lagatol has more than 15 years of experience leading marketing and brand strategy to global organizations. In addition to her expertise promoting consumer packaged goods (CPG) at blue-chip corporations such as Nestle Waters, Sun Products/Henkel, and Unilever as well as startups, she is a former chemist who is dedicated to finding the formula for success in every project.

"Rosie Labs has built an incredible network of individual talents who, when combined in the right mixture for each new client and project, are able to create amazing synergies. By expanding our footprint, we're not only able to offer this secret sauce to more businesses, we can further expand our roster of obsessive and entrepreneurial spirits," said Langatol. "I am proud to take on this new role leading global operations, and Iook forward to spreading our ''obsessivepreneurialism' to help the best, brightest and most innovative attain their goals and reach their full potential."

For more information about Rosie Labs, visit https://www.rosielabs.com/.

About Rosie Labs

Rosie Labs is a marketing services collaborative that brings together experienced professionals and subject matter experts to deliver bespoke, high-impact campaigns to clients such as Rezilion, egglife, Lumineux, Ready Refresh and It Gets Better. Founded by CEO and Managing Director David Song in 2008, Rosie Labs was created to efficiently deliver big ideas and unprecedented results by removing red-tape and bureaucracy. The Rosie Labs network now includes over 100 "obsessivepreneurial" creatives, strategists, producers and hybrids with vast experience across media planning, data analytics, social media, digital advertising, brand management, communications and more. The collaborative is headquartered in New York City, with network members located across the U.S. and beyond.

Cision View original content:https://www.prnewswire.com/news-releases/new-york-city-based-marketing-collaborative-rosie-labs-brings-unique-unagency-approach-to-israeli-startups-with-launch-in-tel-aviv-301394499.html

SOURCE Rosie Labs


Copyright 2021 PR Newswire

THE PINK SHEET RECOVERY FROM YESTERDAY BLOOD BATH, 10-06-2021 $CYBL $FERN $ILUS $IFXY $PJET $$$$$ BIG DOGS

$CYBL ASSOCIATED WIT $CREE [NAME CHANGE COMING FOR $CREE TO WOLF SPEED]
$CREE PARTNER WIT $CYBL

QUICK! A SECRET $0.04 Penny Stock IS DROPPING CRAZY NEWS TONIGHT! EASY $ ??
4,794 viewsOct 7, 2021

Business update: Full disclosure, we are in coordination across multiple time zones in Europe and South America to release the new acquisition news. We will be releasing today as soon as possible!#OperationAlpha #InfrastructureTechnology #Growth

— Cyberlux Corporation - $CYBL (@CyberluxC) October 7, 2021

$ABUS HEARING VIDEO
Twitter Spaces re Moderna v Arbutus Patent Appeal Oral Argument
460 viewsOct 7, 2021

$CYBL

THIS $0.004 PENNY STOCK IS GETTING U.S. COAST GUARD CONTRACTS? Easy 100%? ??
6,756 viewsOct 6, 2021

Interesting stuff $ilus huge catalysts shells pink current $lgbs $amlh $vizc $spqs $fern [ceo & chris kern & advisor] [big one] $cybl $atxg[nft platform][dubai] $civx

video
(URGENT) 4 $0.00 TINY Penny Stocks can EASILY 1000% your Money?! ??
28,668 viewsOct 3, 2021

$IBIO This Under-the-Radar Pharma Company Could Be a Bargain Hunter's Dream
Pre-clinical successes lead to exclusive licensing agreements for iBio.

https://www.fool.com/investing/2021/10/02/this-under-the-radar-pharma-company-could-be-a-bar/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Jeff Little
(TMFWordman5150)
Oct 2, 2021 at 7:31AM
Author Bio
Key Points
iBio's pipeline includes candidates that show promise against killer diseases.
Its proprietary FastPharming System provides rapid scaling-up capabilities.
Exclusive licensing deals bring worldwide commercialization opportunities.
Companies touting successful treatment candidates to fight COVID-19 are in the healthcare spotlight, gaining the attention of investors. Investigational treatments are being developed at a rapid pace by numerous companies of all sizes. This includes biotech companies such as iBio (NYSEMKT:IBIO), an innovator specializing in the manufacturing and production of antibodies and vaccines under development.

iBio's stock price spiked in July of last year following its inclusion in the Russell 2000 and Russell 3000 indexes. But shortly thereafter, investor confidence waned due to a lack of news from its COVID vaccine candidates, leading to a 75% decline in the biotech stock.

Now, a brief renewed interest from investors is the result of exclusive licensing deals and positive pre-clinical studies involving its most promising candidates. Could this be a sign of growth to come?

lab technicians examining a sample.
IMAGE SOURCE: GETTY IMAGES.

Candidates worth supporting to find an effective treatment
iBio has four candidates in its current pipeline, three of which focus on human diseases. It's also developing a vaccine to treat animals for swine fever.

All three of the human health candidates have reached the pre-clinical phase of development, while the vaccine for treating animals has progressed a bit further into clinical development. Among the candidates showing the most promise is what the company has labeled IBIO-202. It's intended to fight the variant strains of the coronavirus by focusing on the neoclapsid (N) protein, which is known to produce a high immune response rate.

In July, iBio posted results of pre-clinical studies involving IBIO-202, showing that the focus on the N protein can help produce T cells that help the body fight the virus. The study results support the idea that current vaccines focused on the spike (S) protein can be effective but might wane over time, leading to the requirement for boosters. By focusing on the N protein in combination with the S protein, the vaccine could be more effective and longer-lasting.

Kristen Kluska of Cantor Fitzgerald noted, "We believe that the company's approach is sound and could potentially support the ongoing global vaccination effort." Cantor currently has a $3 price target on the stock, reflecting an upside potential of more than 170%.

A second candidate in the pipeline that the company is excited about is RTX-003 (renamed as IBIO-101), an antibody developed by RubrYc Therapeutics that targets regulatory T cells (Tregs) used for immunotherapy treatment for cancer. In pre-clinical studies, it showed signs of generating strong anti-tumor responses as both a monotherapy, and in combination with checkpoint inhibitors.

iBio expects to initiate an investigational new drug study within the next 10 months, with CEO Tom Isett saying that the collaboration with RubrYc is a "pivotal milestone for iBio that can create value in multiple ways." The company intends to use its proprietary plant-based FastPharming protein expression system, combined with the artificial intelligence platform of RubrYc, to produce additional cancer therapeutic candidates that are safe and scalable, and at industry-leading speeds.

A unique plant-based system leads to scaled-up capabilities
The FastPharming system is designed for rapid scaling-up of vaccines and therapeutics and works by creating a targeted protein through the leaves of iBio's proprietary plants. As the plants grow, so do the leaves, which are then harvested, and the proteins are separated, cleaned, and formed into a final product. By using plants as the bioreactors, instead of stainless-steel or single-use bioreactors, the system better complies with green initiatives, and the company maintains that the production method shaves months off standard processing times.

In addition to its forward-looking pipeline of candidates, the company has used the FastPharming system to successfully produce vaccines to fight two variations of the flu. The company has a 130,000-square-foot facility with a two-story farming operation that now houses the FastPharming system.

Worldwide exclusive licensing paves the way to a more robust pipeline
In late August, iBio shelled out $5 million to sign a worldwide exclusive licensing agreement with RubrYc, which will allow it to further the development and commercialization of IBIO-101, as well as to have the option to four new molecules developed with RubrYc's artificial intelligence platform. An additional $2.5 million will be paid to RubrYc in December. As part of the deal, iBio also obtained an equity stake in the privately-held company.

This agreement follows an exclusive licensing deal signed with Planet Biotechnology last year, giving iBio rights to Planet's therapeutic candidate ACE2-Fc. That's the foundational candidate iBio is using as part of its current pipeline to develop treatments for the SARS-CoV-2 virus in its efforts to fight COVID variants.

New hype doesn't justify an investment
The intrigue of investing early in an under-the-radar biopharma is enticing. But with the early stages of a therapeutic pipeline comes the risk of lower revenue, higher expenses, and reliance on non-financial news to spike interest.

In the quarter ended June 30, all of these characteristics were visible. Revenue for the quarter decreased by over 50% from the same period last year, and it also showed a decrease of 37% compared to the previous quarter.

Expenses also increased. Research and development costs soared 177% to $10 million for the full fiscal year, driven by higher expenses to support its pipeline and platform technology. Selling, general, and administrative expenses also jumped during the quarter, doubling from the same period a year ago.

The company expects these expenses to continue growing into 2022, but slower than 2021. Meanwhile, losses continue to pile up at over $23 million for the fiscal year, an increase of 41% over 2020. The company does have $97 million in available cash and cash equivalents but has noted that the current cash position would run out in the first calendar quarter of 2023.

For the bargain-hunting investor who doesn't mind taking on some risk, a $1 stock in a company building a pipeline to treat infectious and fatal diseases could be a big winner in five to 10 years. It could also be nonexistent if cash runs out. For those looking for more solid ground, there are probably better options out there.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
Jeff Little has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

$IBIO This Under-the-Radar Pharma Company Could Be a Bargain Hunter's Dream
Pre-clinical successes lead to exclusive licensing agreements for iBio.

https://www.fool.com/investing/2021/10/02/this-under-the-radar-pharma-company-could-be-a-bar/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Jeff Little
(TMFWordman5150)
Oct 2, 2021 at 7:31AM
Author Bio
Key Points
iBio's pipeline includes candidates that show promise against killer diseases.
Its proprietary FastPharming System provides rapid scaling-up capabilities.
Exclusive licensing deals bring worldwide commercialization opportunities.
Companies touting successful treatment candidates to fight COVID-19 are in the healthcare spotlight, gaining the attention of investors. Investigational treatments are being developed at a rapid pace by numerous companies of all sizes. This includes biotech companies such as iBio (NYSEMKT:IBIO), an innovator specializing in the manufacturing and production of antibodies and vaccines under development.

iBio's stock price spiked in July of last year following its inclusion in the Russell 2000 and Russell 3000 indexes. But shortly thereafter, investor confidence waned due to a lack of news from its COVID vaccine candidates, leading to a 75% decline in the biotech stock.

Now, a brief renewed interest from investors is the result of exclusive licensing deals and positive pre-clinical studies involving its most promising candidates. Could this be a sign of growth to come?

lab technicians examining a sample.
IMAGE SOURCE: GETTY IMAGES.

Candidates worth supporting to find an effective treatment
iBio has four candidates in its current pipeline, three of which focus on human diseases. It's also developing a vaccine to treat animals for swine fever.

All three of the human health candidates have reached the pre-clinical phase of development, while the vaccine for treating animals has progressed a bit further into clinical development. Among the candidates showing the most promise is what the company has labeled IBIO-202. It's intended to fight the variant strains of the coronavirus by focusing on the neoclapsid (N) protein, which is known to produce a high immune response rate.

In July, iBio posted results of pre-clinical studies involving IBIO-202, showing that the focus on the N protein can help produce T cells that help the body fight the virus. The study results support the idea that current vaccines focused on the spike (S) protein can be effective but might wane over time, leading to the requirement for boosters. By focusing on the N protein in combination with the S protein, the vaccine could be more effective and longer-lasting.

Kristen Kluska of Cantor Fitzgerald noted, "We believe that the company's approach is sound and could potentially support the ongoing global vaccination effort." Cantor currently has a $3 price target on the stock, reflecting an upside potential of more than 170%.

A second candidate in the pipeline that the company is excited about is RTX-003 (renamed as IBIO-101), an antibody developed by RubrYc Therapeutics that targets regulatory T cells (Tregs) used for immunotherapy treatment for cancer. In pre-clinical studies, it showed signs of generating strong anti-tumor responses as both a monotherapy, and in combination with checkpoint inhibitors.

iBio expects to initiate an investigational new drug study within the next 10 months, with CEO Tom Isett saying that the collaboration with RubrYc is a "pivotal milestone for iBio that can create value in multiple ways." The company intends to use its proprietary plant-based FastPharming protein expression system, combined with the artificial intelligence platform of RubrYc, to produce additional cancer therapeutic candidates that are safe and scalable, and at industry-leading speeds.

A unique plant-based system leads to scaled-up capabilities
The FastPharming system is designed for rapid scaling-up of vaccines and therapeutics and works by creating a targeted protein through the leaves of iBio's proprietary plants. As the plants grow, so do the leaves, which are then harvested, and the proteins are separated, cleaned, and formed into a final product. By using plants as the bioreactors, instead of stainless-steel or single-use bioreactors, the system better complies with green initiatives, and the company maintains that the production method shaves months off standard processing times.

In addition to its forward-looking pipeline of candidates, the company has used the FastPharming system to successfully produce vaccines to fight two variations of the flu. The company has a 130,000-square-foot facility with a two-story farming operation that now houses the FastPharming system.

Worldwide exclusive licensing paves the way to a more robust pipeline
In late August, iBio shelled out $5 million to sign a worldwide exclusive licensing agreement with RubrYc, which will allow it to further the development and commercialization of IBIO-101, as well as to have the option to four new molecules developed with RubrYc's artificial intelligence platform. An additional $2.5 million will be paid to RubrYc in December. As part of the deal, iBio also obtained an equity stake in the privately-held company.

This agreement follows an exclusive licensing deal signed with Planet Biotechnology last year, giving iBio rights to Planet's therapeutic candidate ACE2-Fc. That's the foundational candidate iBio is using as part of its current pipeline to develop treatments for the SARS-CoV-2 virus in its efforts to fight COVID variants.

New hype doesn't justify an investment
The intrigue of investing early in an under-the-radar biopharma is enticing. But with the early stages of a therapeutic pipeline comes the risk of lower revenue, higher expenses, and reliance on non-financial news to spike interest.

In the quarter ended June 30, all of these characteristics were visible. Revenue for the quarter decreased by over 50% from the same period last year, and it also showed a decrease of 37% compared to the previous quarter.

Expenses also increased. Research and development costs soared 177% to $10 million for the full fiscal year, driven by higher expenses to support its pipeline and platform technology. Selling, general, and administrative expenses also jumped during the quarter, doubling from the same period a year ago.

The company expects these expenses to continue growing into 2022, but slower than 2021. Meanwhile, losses continue to pile up at over $23 million for the fiscal year, an increase of 41% over 2020. The company does have $97 million in available cash and cash equivalents but has noted that the current cash position would run out in the first calendar quarter of 2023.

For the bargain-hunting investor who doesn't mind taking on some risk, a $1 stock in a company building a pipeline to treat infectious and fatal diseases could be a big winner in five to 10 years. It could also be nonexistent if cash runs out. For those looking for more solid ground, there are probably better options out there.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
Jeff Little has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

try to get some huge insertion my friend $AAPT

[-chart]www.stockscores.com/chart.asp?TickerSymbol=AAPT&TimeRange=275&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=830&ChartHeight=500&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=RSI&Indicator2=BBW&Indicator3=AccDist&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]

reading my friend Ethema Health Corp. (GRST)'

$GRST>36 STRONG DD POINTS FOR POTENTIAL 1,000%-5,000%-10,000%+ GAINS.

We all have seen many OTC stocks running to 10 cents, 25 cents, 50 cents and some to $1+ with over 5B OS and literally NOTHING in business.

Ethema Health $GRST has below. RARE OTC GOLDEN OPPORTUNITY.

1. Ethema Health is OTC PINK Current Company.

***** LINK *****
https://www.otcmarkets.com/stock/GRST/profile

***** SCREENSHOT from OTC Market website*****



2. Ethema Health's U.S. reporting status is SEC reporting with audited fins.

*****LINK*****
https://www.otcmarkets.com/stock/GRST/profile

*****SCREENSHOT from OTC Market website*****



3. Ethema Health is growing fast and becoming a major OTC company. Organic growth not just pump and dump type.

Check out all the latest developments and press releases at one place in below globenewswire link.

*****LINK*****
https://www.globenewswire.com/search/organization/Ethema%2520Health%2520Corporation

4. Ethema Health - GRST CEO Tweeted on June 29, 2021 that there won't be any Reverse Split in 2021, 2022 and 2023.

*****LINK*****
https://twitter.com/HealthEthema/status/1409883342175096845

*****SCREENSHOT*****


5. Ethema Health NOW owns Addiction Recovery Institute of America (ARIA) Health center.

Ethema Health has already paid off the cost of ARIA in cash and restricted $GRST stocks.

As per below Press Release on June 23, 2021, Ethema got APPROVAL from "Department of Children and Families of Florida".

*****June 23, 2021 (GLOBE NEWSWIRE) - Ethema Acquisition Approved*****
https://www.globenewswire.com/news-release/2021/06/23/2251940/0/en/Ethema-Acquisition-Approved.html

*****SCREENSHOTs from ARIA ACQUISITION APPROVAL.*****


6. For the 1st time ever, Ethema Health $GRST is expected to generate millions of dollars of revenue from ARIA Health Center.

Based on all the developments including full license approval from Florida Department of Children and Family Service, approval from major Health Insurance Providers, ARIA Health Center running at almost full capacity and growing. See above and below DD points.

7. Addiction Recovery Institute of America (ARIA) Health center.

*****ARIA Website LINK*****
https://www.ariafl.com/

*****SCREENSHOTs from ARIA Website*****






8. ARIA provides 25+ rehab, substance abuse treatment and addiction treatment therapy programs.

*****LINK*****
https://www.ariafl.com/florida-drug-alcohol-rehab-programs/

*****SCREENSHOT*****



9. Ethema Health is PROFITABLE.

How many OTC companies trading below $.10 can say they are PROFITABLE? I see 1 and that is $GRST.

*****LINK*****
https://www.globenewswire.com/news-release/2021/04/29/2219805/0/en/Ethema-Acquires-Larger-Interest-in-ARIA-Treatment-Center.html

*****SCREENSHOT from Press Release*****


10. In Jan 2021, ARIA received full license by Department of Children and Family Service for Florida (“DCF”).

*****LINK to Press Release*****
https://www.globenewswire.com/news-release/2021/01/13/2157945/0/en/ARIA-Treatment-Facility-Fully-Licensed.html

*****SCREENSHOT from Press Release*****



11. In early 2021, ARIA was approved by most health insurance companies including BCBS, Humana, Aetna, Cigna.

*****LINKs to Press Release*****
https://www.globenewswire.com/news-release/2021/03/01/2184237/0/en/Ethema-Announces-Blue-Cross-In-Network-Contract-for-ARIA-Treatment-Center.html

https://www.globenewswire.com/news-release/2020/11/25/2133756/0/en/ARIA-Treatment-Center-Receives-LegitScript-Certification-and-Blue-Cross-Provider-Number.html

*****SCREENSHOTs from Press Release*****





12. In Jan 2021 press release $GRST reported that ARIA finished November and December 2020 with out-of-network gross billing of $602,200.00. Since then, ARIA is fully licensed and approved by major health insurance providers.

*****LINK to Press Release*****
https://www.globenewswire.com/news-release/2021/01/13/2157945/0/en/ARIA-Treatment-Facility-Fully-Licensed.html

*****SCREENSHOT from Press Release*****



13. ARIA Health care center is running at almost full capacity. $GRST expanding ARIA to treat more patients.

*****LINK to Press Release*****
https://www.globenewswire.com/news-release/2021/03/01/2184237/0/en/Ethema-Announces-Blue-Cross-In-Network-Contract-for-ARIA-Treatment-Center.html

*****SCREENSHOT from Press Release*****



14. ARIA EMPLOYEES SPOTLIGHT

*****LINK*****
https://www.facebook.com/AddictionRecoveryInstituteOfAmerica/

*****SCREENSHOT*****





15. More GRST Acquisition(Royal Life Centers) Confirmation per CO SOS....

*****LINK*****
https://royallifecenters.com/locations/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164563736

*****SCREENSHOT*****



16. Ethema Health's CEO owns 80.4M $GRST shares @ $0.079 PPS.

*****LINK*****
https://www.secform4.com/filings/792935/0001721868-18-000742.htm

*****SCREENSHOT*****



17. Ethema Health CEO’s son owns 100M $GRST shares.

*****LINK*****
https://www.otcmarkets.com/filing/conv_pdf?id=14873406&guid=KXlUke8-4JRk43h

18. Ethema Health CEO’s wife invested her own millions of dollars.

*****LINK*****
https://www.otcmarkets.com/filing/conv_pdf?id=14979734&guid=KXlUke8-4JRk43h

19. Big Hedge Fund Leonite Capital to get 20% OS @ $0.12 PPS. YES, $0.12. Leonite Capital must be expecting 100%, 200% or 500% gains from $0.12 which could put $GRST PPS @ 20 cents, 50 cents or more.

*****LINK*****
https://www.otcmarkets.com/filing/conv_pdf?id=14979734&guid=KXlUke8-4JRk43h

20. Ethema Health's CEO related to MULTI BILLION DOLLAR LEON business family of Canada.

*****LINK*****
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158769800

https://en.wikipedia.org/wiki/Leon%27s

*****SCREENSHOT*****








21. A few Ethema Health investors have visited ARIA facility in West Palm Beach, FL.

*****LINK*****
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159107297

22. Ethema Health's CEO is transparent, communicates and updates shareholders whenever needed.

All the information about the company in in Quarterly and Annual reports, all timely filed by $GRST. Plus company regularly releases updates and press releases about business development.

*****LINKs to ALL Annual and Quarterly reports filings.*****
https://www.otcmarkets.com/stock/GRST/disclosure

*****LINKs to ALL Press Releases.*****
https://www.globenewswire.com/search/organization/Ethema%2520Health%2520Corporation

23. Ethema Health is active on social media on Facebook and Twitter.

*****LINKs*****

Ethema Health Corporation Website
http://www.ethemahealth.com/

Facebook page
https://www.facebook.com/AddictionRecoveryInstituteOfAmerica/

Twitter page
https://twitter.com/healthethema

*****SCREENSHOT*****


24. Ethema Health has many videos of ARIA health care facility on YouTube.

****LINK to Ethema Health Corp Youtube Channel.
Watch ALL the Videos.
Tour the ARIA Health Facility. *****

https://www.youtube.com/channel/UCq8VpCE_x2ZBEnXWjKgx_rw/videos




*****SCREENSHOT*****


25. Ethema Health has excellent reviews of ARIA health care patients.

*****LINK*****
https://www.google.com/search?q=Addiction+Recovery+Institute+of+America+review&sxsrf=ALeKk03_SLqqeWvgpbVNWXprTluQmxQJhA%3A1622576702081&source=hp&ei=Po62YL__Ade0tQbK54KQCA&iflsig=AINFCbYAAAAAYLacTkOCM38mgicTjs8thVFPzN6DxfZ8&oq=Addiction+Recovery+Institute+of+America+review&gs_lcp=Cgdnd3Mtd2l6EAMyBQghEKABOgQIIxAnOgYIABAWEB46CwguEMcBEK8BEJMCOggIIRAWEB0QHlDSBVjUEWDQFGgAcAB4AIABywKIAaEIkgEHMy40LjAuMZgBAKABAqABAaoBB2d3cy13aXo&sclient=gws-wiz&ved=0ahUKEwi_lsifmffwAhVXWs0KHcqzAIIQ4dUDCAk&uact=5#lrd=0x88d8d775516d8485:0x77f0097b8f8575a3,1,,,

*****SCREENSHOT*****



26. Ethema Health's CEO is an industry veteran with a degree.

*****LINK*****
https://www.wsj.com/market-data/quotes/GRST/company-people/executive-profile/109176791

*****SCREENSHOT*****



27. In addition to ARIA, Ethema Health $GRST opening another revenue stream with a joint venture with Sparta Group.

*****LINK*****
https://www.globenewswire.com/news-release/2021/03/02/2185295/0/en/Ethema-Signs-M-O-U-with-Canadian-based-Sparta-Group-to-Expand-its-Focus-on-its-Pathogen-Protection-Initiatives.html

*****SCREENSHOT*****



28. Ethema Health take cares of the shareholders. Control and much better share structure as compare to other OTC companies.

*****LINK*****
https://www.globenewswire.com/news-release/2021/05/17/2230956/0/en/Ethema-Repays-a-Significant-Portion-of-Its-Convertible-Debt.html

*****SCREENSHOT*****



29. In the past OTC companies with growth, revenues and SS like $GRST have ran to 50 cents to $1+.

Experience OTC traders/investors have seen that all.

30. Ethema Health's CEO has cancelled his own shares.

*****LINK*****
https://www.globenewswire.com/news-release/2020/12/10/2143305/0/en/Ethema-Files-8-K-Cancels-CEO-Shares.html

*****SCREENSHOT*****



31. Ethema Health is way undervalued as compare to other 2 NASDAQ competitors.

*****LINK*****
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158598536

*****SCREENSHOT*****



32. President Joe Biden want to send addicts to addiction treatment centers and NOT jail.

*****LINK*****
Below is the LINK to TRANSCRIPT of Trump & Joe Biden Presidential Debate. Search for words “treatment” and “jail”.
https://www.usatoday.com/story/news/politics/elections/2020/10/23/debate-transcript-trump-biden-final-presidential-debate-nashville/3740152001/

*****SCREENSHOT*****



33. Ethema Health was granted a government assistance loan. One of the few OTC PINK Current companies to get that.

*****LINK*****
https://www.otcmarkets.com/filing/conv_pdf?id=14979734&guid=DSlUkpwMD3fWdyh

*****SCREENSHOT*****



34. Ethema Health Yearly and Weekly Technical chart shows upward move ready to explode for massive gains.

*****LINK*****
https://stockcharts.com/h-sc/ui?s=grst

*****SCREENSHOT*****



35. Ethema Health 2020 10K filed in April shows record $3+ M in NET INCOME after debt extinguishment of $12.6M.

*****LINK*****
https://www.otcmarkets.com/filing/conv_pdf?id=14873406&guid=DSlUkpwMD3fWdyh

*****SCREENSHOT*****



36. Florida's New Gambling Deal With The Seminole Tribe Is Expected To Bring In $500 Million Annually.

*****LINK*****
https://www.wlrn.org/news/2021-05-26/floridas-new-gambling-deal-with-the-seminole-tribe-is-expected-to-bring-in-500-million-annually

*****SCREENSHOT*****



ENJOY $GRST

What Your CPA Isn't Telling You! | Mark J Kohler LIVE |
29,577 viewsStreamed live on Feb 25, 2021

The MOST POPULAR $0.01 PENNY STOCK IS DROPPING NEWS TONIGHT - Dont miss a 10x ??
3,778 viewsSep 16, 2021

Why Every American NEEDs a Trust | Mark J Kohler LIVE | Q&A
218,469 viewsStreamed live on May 27, 2021

$GNCP / $HCMC / $CBDL / $ECEZ / $INCT / $TGRO / $GRSO / $FTEG / $GTEH / $RBNW / $PRPM / $EWLL / $RETC / $PBHG / $BDGR / $RDAR

pinks 09-15-2021

[-chart]pbs.twimg.com/media/E_QjJoeWUAI6XnB?format=jpg&name=900x900[/chart]


https://twitter.com/TheMockSarket/status/1437814935564824580/photo/1